This year, i2i launched the third edition of the "IP2 Scale Out Program," an acceleration initiative for Taiwanese startups to enter the US Market. On June 19th, i2i Chairman Gary Gong led a delegation that included CancerFree, an alumnus from the first cohort, and Preteeth AI, a current participant, on a visit to PharmaEssentia's PIRC (PharmaEssentia Innovation Research Center) in Boston.
The group met with Dr. KuoChong Lin, the founder of PharmaEssentia, to discuss potential collaborations between Taiwan and the U.S. in the biomedical sector.
The PharmaEssentia team provided an overview presentation.
Veteran Entrepreneurs Mentor Next Generation
Dr. KuoChong Lin, who has been a strong supporter of Taiwan’s biotechnology policies, initiated PharmaEssentia back in 2000 by rallying Taiwanese biotech experts from the U.S. to return home.
He expressed his willingness to assist Taiwanese startups aiming to expand into the Eastern U.S. market, offering the resources of PharmaEssentia to help i2i continue its international acceleration efforts.
During the visit, CancerFree and Preteeth AI had the opportunity to present their products and future plans to the PharmaEssentia team. This visit highlighted how experienced companies are actively guiding and mentoring the next generation of innovators in Taiwan's startup and biomedical industries.
A representative from CancerFree delivered a presentation.
A representative from Preteeth AI delivered a presentation.
Comments